BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.11M | -38.80M | -44.76M | -28.44M | -22.06M |
| Total Depreciation and Amortization | 186.00K | 194.00K | 181.00K | 181.00K | 54.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.80M | 2.86M | 8.82M | 486.00K | 944.00K |
| Change in Net Operating Assets | 2.21M | -6.49M | 6.99M | 4.48M | 1.46M |
| Cash from Operations | -35.92M | -42.23M | -28.77M | -23.29M | -19.60M |
| Capital Expenditure | -24.00K | -73.00K | -140.00K | -231.00K | -162.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -285.38M | 7.84M | 40.70M | 9.87M | 15.53M |
| Cash from Investing | -285.41M | 7.77M | 40.56M | 9.64M | 15.37M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 416.00K | 45.00K | 373.46M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 22.22M | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -121.00K | -631.00K | -8.02M | -3.27M | -404.00K |
| Cash from Financing | 295.00K | -586.00K | 365.44M | 18.96M | -404.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -321.03M | -35.05M | 377.22M | 5.30M | -4.64M |